Research ArticleDrug Discovery and Translational Medicine
Identification of Granulocyte Colony-Stimulating Factor and Interleukin-6 as Candidate Biomarkers of CBLB502 Efficacy as a Medical Radiation Countermeasure
Vadim I. Krivokrysenko, Alexander N. Shakhov, Vijay K. Singh, Frederick Bone, Yevgeniy Kononov, Inna Shyshynova, Alec Cheney, Ratan K. Maitra, Andrei Purmal, Mark H. Whitnall, Andrei V. Gudkov and Elena Feinstein
Journal of Pharmacology and Experimental Therapeutics November 2012, 343 (2) 497-508; DOI: https://doi.org/10.1124/jpet.112.196071
Vadim I. Krivokrysenko
Cleveland BioLabs, Inc., Buffalo, New York (V.I.K., A.N.S., F.B., Y.K., I.S., A.C., R.K.M., A.P., A.V.G., E.F.); Department of Radiation Biology, F. Edward Hébert School of Medicine (V.K.S.) and Radiation Countermeasures Program, Armed Forces Radiobiology Research Institute (V.K.S., M.H.W.), Uniformed Services University of the Health Sciences, Bethesda, Maryland; and Department of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, New York (A.V.G.)
Alexander N. Shakhov
Cleveland BioLabs, Inc., Buffalo, New York (V.I.K., A.N.S., F.B., Y.K., I.S., A.C., R.K.M., A.P., A.V.G., E.F.); Department of Radiation Biology, F. Edward Hébert School of Medicine (V.K.S.) and Radiation Countermeasures Program, Armed Forces Radiobiology Research Institute (V.K.S., M.H.W.), Uniformed Services University of the Health Sciences, Bethesda, Maryland; and Department of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, New York (A.V.G.)
Vijay K. Singh
Cleveland BioLabs, Inc., Buffalo, New York (V.I.K., A.N.S., F.B., Y.K., I.S., A.C., R.K.M., A.P., A.V.G., E.F.); Department of Radiation Biology, F. Edward Hébert School of Medicine (V.K.S.) and Radiation Countermeasures Program, Armed Forces Radiobiology Research Institute (V.K.S., M.H.W.), Uniformed Services University of the Health Sciences, Bethesda, Maryland; and Department of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, New York (A.V.G.)
Frederick Bone
Cleveland BioLabs, Inc., Buffalo, New York (V.I.K., A.N.S., F.B., Y.K., I.S., A.C., R.K.M., A.P., A.V.G., E.F.); Department of Radiation Biology, F. Edward Hébert School of Medicine (V.K.S.) and Radiation Countermeasures Program, Armed Forces Radiobiology Research Institute (V.K.S., M.H.W.), Uniformed Services University of the Health Sciences, Bethesda, Maryland; and Department of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, New York (A.V.G.)
Yevgeniy Kononov
Cleveland BioLabs, Inc., Buffalo, New York (V.I.K., A.N.S., F.B., Y.K., I.S., A.C., R.K.M., A.P., A.V.G., E.F.); Department of Radiation Biology, F. Edward Hébert School of Medicine (V.K.S.) and Radiation Countermeasures Program, Armed Forces Radiobiology Research Institute (V.K.S., M.H.W.), Uniformed Services University of the Health Sciences, Bethesda, Maryland; and Department of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, New York (A.V.G.)
Inna Shyshynova
Cleveland BioLabs, Inc., Buffalo, New York (V.I.K., A.N.S., F.B., Y.K., I.S., A.C., R.K.M., A.P., A.V.G., E.F.); Department of Radiation Biology, F. Edward Hébert School of Medicine (V.K.S.) and Radiation Countermeasures Program, Armed Forces Radiobiology Research Institute (V.K.S., M.H.W.), Uniformed Services University of the Health Sciences, Bethesda, Maryland; and Department of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, New York (A.V.G.)
Alec Cheney
Cleveland BioLabs, Inc., Buffalo, New York (V.I.K., A.N.S., F.B., Y.K., I.S., A.C., R.K.M., A.P., A.V.G., E.F.); Department of Radiation Biology, F. Edward Hébert School of Medicine (V.K.S.) and Radiation Countermeasures Program, Armed Forces Radiobiology Research Institute (V.K.S., M.H.W.), Uniformed Services University of the Health Sciences, Bethesda, Maryland; and Department of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, New York (A.V.G.)
Ratan K. Maitra
Cleveland BioLabs, Inc., Buffalo, New York (V.I.K., A.N.S., F.B., Y.K., I.S., A.C., R.K.M., A.P., A.V.G., E.F.); Department of Radiation Biology, F. Edward Hébert School of Medicine (V.K.S.) and Radiation Countermeasures Program, Armed Forces Radiobiology Research Institute (V.K.S., M.H.W.), Uniformed Services University of the Health Sciences, Bethesda, Maryland; and Department of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, New York (A.V.G.)
Andrei Purmal
Cleveland BioLabs, Inc., Buffalo, New York (V.I.K., A.N.S., F.B., Y.K., I.S., A.C., R.K.M., A.P., A.V.G., E.F.); Department of Radiation Biology, F. Edward Hébert School of Medicine (V.K.S.) and Radiation Countermeasures Program, Armed Forces Radiobiology Research Institute (V.K.S., M.H.W.), Uniformed Services University of the Health Sciences, Bethesda, Maryland; and Department of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, New York (A.V.G.)
Mark H. Whitnall
Cleveland BioLabs, Inc., Buffalo, New York (V.I.K., A.N.S., F.B., Y.K., I.S., A.C., R.K.M., A.P., A.V.G., E.F.); Department of Radiation Biology, F. Edward Hébert School of Medicine (V.K.S.) and Radiation Countermeasures Program, Armed Forces Radiobiology Research Institute (V.K.S., M.H.W.), Uniformed Services University of the Health Sciences, Bethesda, Maryland; and Department of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, New York (A.V.G.)
Andrei V. Gudkov
Cleveland BioLabs, Inc., Buffalo, New York (V.I.K., A.N.S., F.B., Y.K., I.S., A.C., R.K.M., A.P., A.V.G., E.F.); Department of Radiation Biology, F. Edward Hébert School of Medicine (V.K.S.) and Radiation Countermeasures Program, Armed Forces Radiobiology Research Institute (V.K.S., M.H.W.), Uniformed Services University of the Health Sciences, Bethesda, Maryland; and Department of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, New York (A.V.G.)
Elena Feinstein
Cleveland BioLabs, Inc., Buffalo, New York (V.I.K., A.N.S., F.B., Y.K., I.S., A.C., R.K.M., A.P., A.V.G., E.F.); Department of Radiation Biology, F. Edward Hébert School of Medicine (V.K.S.) and Radiation Countermeasures Program, Armed Forces Radiobiology Research Institute (V.K.S., M.H.W.), Uniformed Services University of the Health Sciences, Bethesda, Maryland; and Department of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, New York (A.V.G.)
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleDrug Discovery and Translational Medicine
Identification of CBLB502 Efficacy Biomarkers
Vadim I. Krivokrysenko, Alexander N. Shakhov, Vijay K. Singh, Frederick Bone, Yevgeniy Kononov, Inna Shyshynova, Alec Cheney, Ratan K. Maitra, Andrei Purmal, Mark H. Whitnall, Andrei V. Gudkov and Elena Feinstein
Journal of Pharmacology and Experimental Therapeutics November 1, 2012, 343 (2) 497-508; DOI: https://doi.org/10.1124/jpet.112.196071
Research ArticleDrug Discovery and Translational Medicine
Identification of CBLB502 Efficacy Biomarkers
Vadim I. Krivokrysenko, Alexander N. Shakhov, Vijay K. Singh, Frederick Bone, Yevgeniy Kononov, Inna Shyshynova, Alec Cheney, Ratan K. Maitra, Andrei Purmal, Mark H. Whitnall, Andrei V. Gudkov and Elena Feinstein
Journal of Pharmacology and Experimental Therapeutics November 1, 2012, 343 (2) 497-508; DOI: https://doi.org/10.1124/jpet.112.196071
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement